DexCom Inc

Latest DexCom Inc News and Updates

  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott’s Freestyle Libre Gets Reimbursement Approval in France

    Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.

    By Sarah Collins
  • uploads///equipment _
    Company & Industry Overviews

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

    By Kenneth Smith
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

    By Kenneth Smith
  • uploads///Diabetes
    Company & Industry Overviews

    A Look into Johnson & Johnson’s Diabetes Care Business

    In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    What to Expect from Tandem’s Product Pipeline

    T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.

    By Kenneth Smith
  • uploads///GUARDIAN SENSOR
    Company & Industry Overviews

    FDA Approves Arm Indication for Medtronic’s Guardian Sensor 3

    On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3.

    By Sarah Collins
  • uploads///MINIMED MIO
    Company & Industry Overviews

    Medtronic Strengthens Diabetes Business with MiniMed Infusion Set

    On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.

    By Sarah Collins
  • uploads///freestyle libre
    Company & Industry Overviews

    Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval

    On September 27, Abbott Laboratories (ABT) announced the FDA approval of its Flash CGM (continuous glucose monitoring) device, Freestyle Libre.

    By Sarah Collins
  • Company & Industry Overviews

    What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?

    The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.

    By David Ashworth
  • uploads///ONETOUCH
    Company & Industry Overviews

    Johnson & Johnson’s Latest Medical Device Launches

    Johnson & Johnson has announced the schedule for the launch of the OneTouch Via insulin patch. It plans to launch the device in select US markets by the end of 2016.

    By Sarah Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.